UP!
Aerie Pharmaceuticals (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.32 | -0.32 |
| Q1 2022 | 2022-05-05 | -0.66 | -0.66 |
| Q4 2021 | 2022-02-24 | 1.09 | 1.09 |
| Q3 2021 | 2021-11-04 | -0.72 | -0.72 |
| Q2 2021 | 2021-08-04 | -0.67 | -0.67 |
| Q1 2021 | 2021-05-05 | -0.72 | -0.72 |
| Q4 2020 | 2021-02-25 | -0.79 | -0.79 |
| Q3 2020 | 2020-11-05 | -0.65 | -0.65 |
| Q2 2020 | 2020-08-06 | -0.83 | -0.83 |
| 2016-06-02 | Initiated Coverage | Cantor Fitzgerald | Buy | $44.00 |
| 2016-05-16 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-03 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-05-03 | Reiterated Rating | Brean Capital | Buy | |
| 2016-04-07 | Reiterated Rating | Brean Capital | Buy | |
| 2016-03-19 | Reiterated Rating | Cantor Fitzgerald | Buy | $40.00 |
| 2016-03-19 | Reiterated Rating | Brean Capital | Buy | |
| 2016-03-05 | Reiterated Rating | RBC Capital | Buy | |
| 2016-03-05 | Reiterated Rating | Brean Capital | Buy | $48.00 |
| 2016-03-05 | Reiterated Rating | Royal Bank Of Canada | Buy | |
| 2016-02-21 | Reiterated Rating | RBC Capital | Outperform | $50.00 |
| 2016-02-18 | Reiterated Rating | Canaccord Genuity | Buy | $44.00 |
| 2016-01-07 | Reiterated Rating | Brean Capital | Buy | $48.00 |
| 2015-12-02 | Reiterated Rating | Cantor Fitzgerald | Buy | $40.00 |
| 2015-11-05 | Reiterated Rating | Canaccord Genuity | Buy | $44.00 |
| 2015-11-04 | Boost Price Target | RBC Capital | Outperform | $44.00 to $50.00 |
| 2015-10-02 | Reiterated Rating | Brean Capital | Buy | |
| 2015-09-17 | Boost Price Target | Cantor Fitzgerald | Buy | $30.00 to $40.00 |
| 2015-09-17 | Boost Price Target | Canaccord Genuity | Buy | $40.00 to $44.00 |
| 2015-09-17 | Boost Price Target | JMP Securities | Outperform | $39.00 to $49.00 |
| 2015-09-17 | Boost Price Target | Needham & Company LLC | Buy | $27.00 to $45.00 |
| 2015-09-17 | Boost Price Target | Brean Capital | Buy | $33.00 to $48.00 |
| 2015-09-17 | Boost Price Target | Stifel Nicolaus | Buy | $30.00 to $40.00 |
| 2015-09-17 | Boost Price Target | RBC Capital | Outperform | $31.00 to $44.00 |
| 2015-09-10 | Reiterated Rating | Brean Capital | Buy | $33.00 |
| 2015-09-09 | Initiated Coverage | JMP Securities | Outperform | $39.00 |
| 2015-08-06 | Reiterated Rating | Cantor Fitzgerald | Buy | $30.00 |
| 2015-08-06 | Reiterated Rating | Canaccord Genuity | Buy | $40.00 |
| 2015-08-06 | Reiterated Rating | Brean Capital | Buy | $33.00 |
| 2015-07-17 | Boost Price Target | Brean Capital | Buy | $24.00 to $33.00 |
| 2015-06-19 | Upgrade | Canaccord Genuity | Hold to Buy | $40.00 |
| 2015-06-16 | Boost Price Target | Cantor Fitzgerald | Buy | $15.00 to $30.00 |
| 2015-06-16 | Boost Price Target | RBC Capital | Outperform | $27.00 to $31.00 |
| 2015-06-16 | Upgrade | Needham & Company LLC | Hold to Buy | $13.27 to $27.00 |
| 2015-06-05 | Reiterated Rating | Piper Jaffray | Buy | $7.00 to $9.00 |
| 2015-06-05 | Reiterated Rating | Piper Jaffray Cos. | Buy | $7.00 to $9.00 |
| 2015-06-03 | Reiterated Rating | Brean Capital | Buy | $24.00 |
| 2015-06-02 | Set Price Target | Canaccord Genuity | Hold | $12.00 |
| 2015-05-08 | Upgrade | Cantor Fitzgerald | Hold to Buy | $15.00 |
| 2015-04-24 | Downgrade | Needham & Company LLC | Buy to Hold | |
| 2015-04-24 | Lower Price Target | Stifel Nicolaus | Buy | $40.00 to $30.00 |
| 2015-04-24 | Lower Price Target | RBC Capital | Outperform | $50.00 to $27.00 |
| 2015-04-24 | Downgrade | Canaccord Genuity | Buy to Hold | $40.00 to $12.00 |
| 2015-04-24 | Downgrade | Cantor Fitzgerald | Buy to Hold | $12.00 |
| 2015-04-24 | Lower Price Target | Brean Capital | Buy | $46.00 to $24.00 |
| 2015-04-16 | Boost Price Target | RBC Capital | Outperform | $45.00 to $50.00 |
| 2015-03-25 | Reiterated Rating | Cantor Fitzgerald | Buy | $40.00 |
| 2015-03-24 | Reiterated Rating | MLV & Co. | Buy | $40.00 |
| 2015-03-24 | Initiated Coverage | Brean Capital | Buy | $46.00 |
| 2015-01-20 | Reiterated Rating | Canaccord Genuity | Buy | $40.00 |
| 2015-01-08 | Reiterated Rating | MLV & Co. | Buy | $40.00 |
| 2015-01-07 | Initiated Coverage | Cantor Fitzgerald | Buy | $40.00 |
| 2014-07-17 | Boost Price Target | RBC Capital | Outperform | $36.00 to $41.00 |
| 2014-07-03 | Initiated Coverage | Canaccord Genuity | Buy | $40.00 |
| 2014-06-26 | Reiterated | Needham | Buy | $26 to $37 |
| 2014-06-26 | Boost Price Target | RBC Capital | Outperform | $27.00 to $36.00 |
| 2014-06-26 | Boost Price Target | Needham & Company LLC | Buy | $26.00 to $37.00 |
| 2014-05-13 | Lower Price Target | RBC Capital | Outperform | $28.00 to $27.00 |
| 2014-03-19 | Reiterated | RBC Capital Mkts | Outperform | $25 to $28 |
| 2014-03-19 | Reiterated | Needham | Buy | $22 to $26 |
| 2014-03-19 | ||||
| 2014-03-19 | Boost Price Target | Stifel Nicolaus | Positive to Buy | $22.00 to $24.00 |
| 2014-03-19 | Boost Price Target | RBC Capital | Outperform | $25.00 to $28.00 |
| 2014-03-19 | Boost Price Target | Needham & Company LLC | Buy | $22.00 to $26.00 |
| 2013-12-03 | Initiated Coverage | Needham & Company LLC | Buy | $18.00 |
| 2013-11-19 | Initiated | Stifel | Buy | $18 |
| 2013-11-19 | Initiated | RBC Capital Mkts | Outperform | $20 |
| 2013-11-19 | Initiated Coverage | Canaccord Genuity | Buy to Buy | $19.00 |
| 2013-11-19 | Initiated Coverage | RBC Capital | Outperform | $20.00 |
| 2013-11-19 | Initiated Coverage | Stifel Nicolaus | Buy | $18.00 |
| 2016-06-02 | Initiated Coverage | Cantor Fitzgerald | Buy | $44.00 |
| 2016-05-16 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-03 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-05-03 | Reiterated Rating | Brean Capital | Buy | |
| 2016-04-07 | Reiterated Rating | Brean Capital | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AERI 135 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| DEERFIELD MANAGEMENT CO | 4.86M |
| BlackRock Inc. | 3.54M |
| Vanguard Group, Inc | 2.44M |
| UBS Group AG | 2.41M |
| Jefferies Group LLC | 2.36M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 2.09M |
| WATER ISLAND CAPITAL LLC | 2.08M |
| BlackRock Fund Advisors | 1.63M |
| RICE HALL JAMES & ASSOCIATES, LLC | 1.60M |
| MORGAN STANLEY | 1.32M |
| LEVIN CAPITAL STRATEGIES, L.P. | 1.13M |
| CITIGROUP INC | 1.10M |
| BANK OF AMERICA CORP /DE/ | 1.08M |
| CNH PARTNERS LLC | 1.08M |
| ALPINE ASSOCIATES MANAGEMENT INC. | 1.03M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Clarus Lifesciences II, L.P. | 14.52% (3468494) | ACHN / AERI / NSTG / OPHT / TLOG / |
| TPG Group Holdings (SBS) Advisors, Inc. | 8.74% (2087466) | AERI / ALDR / CDNA / CZR / EPRS / FSL / GPK / IMS / LPLA / MGNX / NCLH / NTI / OTIC / PKY / Q / ROKA / SABR / SCAI / SUP / TIPT / TMHC / TNDM / VCYT / ZMH / |
| Foresite Capital Management II, LLC | 8.16% (1950477) | AERI / |
| ACP IV, L.P. | 2.58% (616099) | AERI / |
| Mehra Anand | 1.97% (469591) | AERI / MRNS / |
| RUBINO RICHARD J Chief Financial Officer | 1.76% (420293) | AERI / |
| Kopczynski Casey C. Chief Scientific Officer | 0.81% (193061) | AERI / |
| ANIDO VICENTE JR Chief Executive Officer | 0.55% (130777) | AERI / DEPO / |
| MITRO THOMAS A President and COO | 0.23% (54296) | AERI / |
| LaRocca John General Counsel | 0.08% (18000) | AERI / |
| LEVY BRIAN Chief Medical Officer | 0.07% (16313) | AERI / |
| Cagle Gerald D. | 0.06% (14050) | AERI / CLSD / |
| GOLDBERG MURRAY A | 0.02% (4550) | AERI / REGN / |
| MCGRAW BENJAMIN F III | 0.02% (4550) | AERI / |
| DUYK GEOFFREY M | 0.01% (3400) | AERI / AMRS / EPRS / |
| Croarkin Richard | 0.01% (2850) | AERI / CLSD / |
| du Toit Michael | 0.01% (2850) | AERI / EVDY / |
| McHugh Julie | 0.01% (2850) | AERI / ENDP / EPRS / IRWD / LNTH / TRVN / VPHM / |
| GRYSKA DAVID W | 0.01% (1700) | AERI / HPTX / INCY / PDLI / SGEN / |
UM